Hummingbird Bioscience

Singapore
Woodlands, North Region, Singapore, 117604

Company profile

Hummingbird Bioscience company profile

Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$1M-$10M
Founded
2014-01-01, Year

Headquarters

Postal code
117604
Country code
SG
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
3
Total equity funding
$150M
Last funding
Series C / $125M / 2021-05-18
Last equity funding
Series C / $125M
Investors
23
Lead investors
6
Founders
2
Articles
78

Founders and investors

Founders

Jerome Boyd-KirkupPiers Ingram

Lead investors

Decheng CapitalMirae Asset Venture InvestmentNovo HoldingsOCTAVE CapitalSeeds CapitalSK Holdings

Investors

Ally Bridge GroupDecheng CapitalEDBINovo HoldingsPolaris Partners